XOMA/$XOMA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About XOMA

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Ticker

$XOMA
Sector
Primary listing

Employees

13

XOMA Metrics

BasicAdvanced
$396M
-
-$1.37
1.00
-

What the Analysts think about XOMA

Analyst ratings (Buy, Hold, Sell) for XOMA stock.

Bulls say / Bears say

Strong Q1 2025 profitability and revenue growth: XOMA reported total income and revenues of $15.9 million and net income of $2.4 million in Q1 2025, compared to $1.5 million in revenues and an $8.6 million net loss a year earlier, demonstrating significant operational leverage and milestone achievements (GlobeNewswire).
Strategic late-stage portfolio expansion: In May 2025, XOMA acquired mezagitamab royalty and milestone rights from BioInvent for up to $30 million, increasing its stake in a Phase 3 asset with potential near-term commercial milestones and royalty streams (GlobeNewswire).
Diversified portfolio with multiple catalysts: XOMA’s portfolio spans over 120 assets, including six commercial products (e.g., VABYSMO®, OJEMDA™) and 11 Phase 3 programs, with anticipated 2025 catalysts—such as the EMA decision on tovorafenib and topline data for ersodetug—that could drive additional milestone payments (GlobeNewswire).
Rising research and development expenses: R&D spending climbed to $1.3 million in Q1 2025 from just $33 000 a year earlier, reflecting higher pass-through licensing fees and trial costs that may pressure margins if revenue growth slows (GlobeNewswire).
Declining cash reserves: Cash and cash equivalents decreased to $95.0 million at March 31, 2025 from $106.4 million at December 31, 2024 due to acquisitions and share repurchases, signaling potential liquidity constraints if milestone and royalty receipts decelerate (GlobeNewswire).
Receivables impairment risk: In full-year 2024, XOMA recorded $30.9 million in non-cash credit losses on purchased receivables, highlighting the risk of impairment in its royalty receivables portfolio (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Aug 2025.

XOMA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

XOMA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XOMA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs